ID25469A - Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya - Google Patents

Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya

Info

Publication number
ID25469A
ID25469A IDW20001303A ID20001303A ID25469A ID 25469 A ID25469 A ID 25469A ID W20001303 A IDW20001303 A ID W20001303A ID 20001303 A ID20001303 A ID 20001303A ID 25469 A ID25469 A ID 25469A
Authority
ID
Indonesia
Prior art keywords
sefalosporine
christalography
amorf
stories
making
Prior art date
Application number
IDW20001303A
Other languages
English (en)
Inventor
Masahiro Onodera
Masamichi Sukegawa
Kiyoshi Yasui
Tatsuo Watanabe
Toyomi Sato
Yasushi Muria
Katsuharu Iinuma
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of ID25469A publication Critical patent/ID25469A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
IDW20001303A 1998-01-07 1999-01-07 Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya ID25469A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP192098 1998-01-07

Publications (1)

Publication Number Publication Date
ID25469A true ID25469A (id) 2000-10-05

Family

ID=11515039

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001303A ID25469A (id) 1998-01-07 1999-01-07 Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya

Country Status (23)

Country Link
US (2) US6342493B1 (id)
EP (1) EP1051978B1 (id)
JP (1) JP3413406B2 (id)
KR (1) KR100435315B1 (id)
CN (1) CN1151845C (id)
AU (1) AU736555B2 (id)
BR (1) BRPI9907084B8 (id)
CA (1) CA2316841C (id)
CZ (1) CZ302082B6 (id)
EA (1) EA002881B1 (id)
ES (1) ES2393972T3 (id)
HK (1) HK1035148A1 (id)
HU (1) HU230295B1 (id)
ID (1) ID25469A (id)
IL (2) IL137004A0 (id)
NZ (1) NZ505871A (id)
PL (1) PL194097B1 (id)
PT (1) PT1051978E (id)
SK (1) SK286631B6 (id)
TR (1) TR200001903T2 (id)
TW (1) TW587946B (id)
UA (1) UA70311C2 (id)
WO (1) WO1999034832A1 (id)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302082B6 (cs) * 1998-01-07 2010-09-29 Meiji Seika Kaisha Ltd. Prostredek zahrnující krystalograficky stabilní amorfní cefalosporin a zpusob jeho výroby
PE20010635A1 (es) 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
DE60230934D1 (de) 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
AU2002253642B2 (en) * 2001-04-26 2007-05-24 Meiji Seika Kaisha, Ltd. Amorphous cefditoren pivoxil composition and process for producing the same
EP1555024B1 (en) * 2002-10-02 2010-09-29 Meiji Seika Kaisha Ltd. Antibacterial medicinal composition of enhanced oral absorptivity
ES2518316T3 (es) 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
DE602004016831D1 (de) * 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
US20070167402A1 (en) * 2003-06-20 2007-07-19 Meiji Seika Kaisha, Ltd. Product of coprecipitation of sparingly soluble substance and water-soluble polymer and process for producing the same
PT1671635E (pt) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Composição de antibiótico amorfo contendo cefditoreno pivoxil
EP1689755A2 (en) * 2003-11-07 2006-08-16 Ranbaxy Laboratories Limited Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
WO2005082330A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same
CA2568914C (en) 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
CN101560216B (zh) * 2009-05-27 2011-06-15 上海交通大学 头孢妥仑酯的制备方法
US20130143857A1 (en) * 2010-07-23 2013-06-06 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
JPWO2012043700A1 (ja) 2010-09-30 2014-02-24 富山化学工業株式会社 ６−フルオロ−３−ヒドロキシ−２−ピラジンカルボキサミドのナトリウム塩
EP2623497B1 (en) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
PL2861608T3 (pl) 2012-06-19 2019-09-30 Debiopharm International Sa Pochodne prolekowe (e)-n-metylo-n-((3-metylobenzofuran-2-ylo)metylo)-3-(7-okso-5,6,7,8-tetrahydro-1,8-naftyrydyn-3-ylo)akryloamidu
MX371021B (es) * 2013-08-29 2020-01-13 Cadila Healthcare Ltd Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
US10751351B2 (en) 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
CN109053768A (zh) * 2018-08-07 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种无定型头孢妥仑酯的制备方法
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN112190539B (zh) * 2020-11-10 2021-11-02 深圳立健药业有限公司 一种头孢妥仑匹酯组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH05306227A (ja) * 1992-04-27 1993-11-19 Lion Corp 徐放性口腔内疾患治療剤
JP2576927B2 (ja) * 1992-05-15 1997-01-29 ファイザー製薬株式会社 細粒核
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
AR004014A1 (es) * 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
DE69721290T2 (de) * 1996-09-20 2004-01-22 Meiji Seika Kaisha Ltd. Kristalline substanz von pivoxilcefditoren und verfahren zu ihrer herstellung
CZ302082B6 (cs) * 1998-01-07 2010-09-29 Meiji Seika Kaisha Ltd. Prostredek zahrnující krystalograficky stabilní amorfní cefalosporin a zpusob jeho výroby

Also Published As

Publication number Publication date
EA002881B1 (ru) 2002-10-31
IL137004A0 (en) 2001-06-14
CZ302082B6 (cs) 2010-09-29
SK286631B6 (sk) 2009-02-05
TR200001903T2 (tr) 2000-11-21
KR20010033961A (ko) 2001-04-25
HUP0101272A3 (en) 2002-07-29
BRPI9907084B1 (pt) 2017-04-25
US6486149B2 (en) 2002-11-26
HUP0101272A2 (hu) 2001-12-28
BRPI9907084B8 (pt) 2021-05-25
UA70311C2 (uk) 2004-10-15
EP1051978A1 (en) 2000-11-15
CN1290177A (zh) 2001-04-04
IL137004A (en) 2008-11-03
CZ20002542A3 (cs) 2000-12-13
ES2393972T3 (es) 2013-01-03
PT1051978E (pt) 2012-11-20
EP1051978B1 (en) 2012-08-22
CA2316841A1 (en) 1999-07-15
BR9907084A (pt) 2000-10-17
WO1999034832A8 (fr) 1999-10-28
CN1151845C (zh) 2004-06-02
HK1035148A1 (en) 2001-11-16
AU736555B2 (en) 2001-08-02
NZ505871A (en) 2002-10-25
TW587946B (en) 2004-05-21
JP3413406B2 (ja) 2003-06-03
US20020037322A1 (en) 2002-03-28
AU1784599A (en) 1999-07-26
ES2393972T8 (es) 2013-02-25
SK10262000A3 (sk) 2001-01-18
US6342493B1 (en) 2002-01-29
CA2316841C (en) 2007-11-20
WO1999034832A1 (fr) 1999-07-15
EP1051978A4 (en) 2007-05-02
EA200000742A1 (ru) 2001-02-26
HU230295B1 (hu) 2015-12-28
PL194097B1 (pl) 2007-04-30
PL341589A1 (en) 2001-04-23
KR100435315B1 (ko) 2004-06-10

Similar Documents

Publication Publication Date Title
ID25469A (id) Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya
ID19290A (id) Turunan-turunan propiofenon dan proses pembuatannya
ID15947A (id) Senyawa fenol dan proses pembuatannya
ID27408A (id) Benda penyerap dan proses pembuatannya
ID17307A (id) Komposisi oral dan proses pembuatannya.
ID24929A (id) Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya
ID18047A (id) Proses pembuatan bahan antara untuk florfenikol
ID23557A (id) Poliester baru dan proses pembuatan poliester
ID26172A (id) Proses pembuatan surfaktan-surfaktan alkilbenzenasulfonat dan produk-produknya
ID16862A (id) Komposisi-komposisi elastomer dan metoda-metoda pembuatannya
ID20440A (id) Partikel-partikel silika amorf yang memiliki struktur ganda, proses produksinya dan penggunaannya
ID30506A (id) Proses pengembangan ko-produksi 6-aminokapronitril dan heksametilenadiamino
ID23985A (id) Baterai dan metode pembuatannya
ID27814A (id) Pengolahan-awal kostik bekas dan proses oksidasi yang diperkaya
ID23963A (id) Proses pembuatan vinil asetat
ID19385A (id) Adesif termosetting dan metoda pembuatannya
ID24070A (id) Katalis yang mengandung hologen dan proses pembuatannya
ID15992A (id) Papan lamina dan proses pembuatannya
ID18661A (id) Rakitan penyaringan menara proses kimia
ID20137A (id) Turunan propanolamina, proses pembuatannya, sediaan farmasi yang mengandung senyawa ini, dan penggunannya
ID22911A (id) Turunan-turunan triazol baru, proses pembuatan dan komposisi-komposisi farmasi yang mengandungnya
ID28025A (id) Metode pembuatan aminonitril dan diamina
ID23304A (id) Turunan-turunan diaza-spiro [3,5] nonana, proses pembuatan dan penggunaannya
ID20624A (id) Proses pembuatan 2'-flouro-5-metil-betha-l-rabinofuranosiluridin
GB9808264D0 (en) Biochemical devices and their methods of manufacture